Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Data from phase I/II study of NBI-3001 presented at German Society of Neurosurgery

June 11, 1999

Dendreon moves ahead with dendritic cell therapies for cancer

June 10, 1999

Maxamine plus IL-2 prolongs duration of complete remission in patients with AML

June 10, 1999

European Commission issues first approval for tasonermin

June 8, 1999

LifeTime and Dovetail enter exclusive agreement for Beta LT anticancer compound

June 8, 1999

AVI BioPharma to initiate phase II clinical trial of Avicine in pancreatic cancer

June 7, 1999

Additional phase II data suggest modifications for AVI BioPharma's cancer vaccine

June 1, 1999

Phase II trial of York Medical's cancer vaccine cleared

June 1, 1999

Ilex reports progress on Campath development at annual meeting

May 31, 1999

Encouraging phase I trials results for Prostvac presented at ASCO

May 27, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...